IDEXX Laboratories expands parasite testing ahead of IDEXX Laboratories stock results

IDEXX Laboratories (ISIN US45168D1046) was trading at EUR 461.05 at Lang & Schwarz on October 1, 2026 at 12:45 p.m. CEST, up 0.03 percent from the prior close of EUR 460.90. According to IDEXX Laboratories on September 17, 2026, the company expanded its Faecal Dx antigen testing platform in the United Kingdom with Taeniid tapeworm detection.

Testing expansion adds a fresh product signal

The platform expansion follows IDEXX Laboratories' September 16, 2026 acquisition of CoVetAI, a provider of AI-native ambient listening and clinical workflow software for veterinary practices, according to IDEXX Laboratories. Together, the announcements show a product strategy that combines diagnostic testing with workflow software rather than relying on a single instrument cycle.

The latest reported quarter supplies the financial anchor. Zacks reported that second-quarter 2026 revenue increased 10.00 percent year over year to USD 1.22 billion, while diluted earnings per share rose 18.00 percent to USD 4.27 and exceeded consensus by 8.10 percent. Operating margin reached 35.00 percent, an increase of 140 basis points from the prior-year quarter.

Guidance leaves growth expectations elevated

IDEXX Laboratories raised its fiscal 2026 diluted earnings per share outlook to USD 14.69-14.94 from USD 14.45-14.90, while revenue guidance was narrowed to USD 4.70-4.75 billion from USD 4.68-4.76 billion, according to Zacks. The guidance change matters because the company is expanding commercial and diagnostic capabilities while veterinary office visits remain a near-term operating variable.

At the September 14, 2026 Morgan Stanley conference, management said second-half 2026 veterinary office visits were expected to decline 1.50 percent to 2.00 percent, while comparable operating margin expansion was expected at 20 to 50 basis points in the second-half quarters, as reported by Investing.com. That contrast leaves utilization and recurring diagnostic revenue as the central operating indicators.

Stock stays below its yearly range

IDEXX Laboratories stock was trading at EUR 461.05 at Lang & Schwarz on October 1, 2026 at 12:45 p.m. CEST, versus EUR 460.90 at the prior close. The primary Nasdaq listing had a 52-week range of USD 500.61 to USD 769.98 as of September 30, 2026, while market capitalization stood at USD 41.2 billion.

The further course of trading is shown by the continuously updated real-time quote of IDEXX Laboratories stock.

More news and analyses on IDEXX Laboratories stock